You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》內地第二大疫苗製造企業艾美疫苗遞主板上市申請
阿思達克 06-30 11:58
內地第二大疫苗製造企業艾美疫苗股份已提交主板上市申請,聯席保薦人為高盛、中金、中信建投國際、麥格理。

據初步招股文件顯示,艾美疫苗是國內最大的全產業鏈民營疫苗集團,在去年取得了約6,000萬劑的批簽發量,同時也是內地僅次於中國生物的第二大疫苗製造企業。

公司目前已商業化8款針對6個疾病領域的疫苗產品,包括狂犬病、乙型肝炎、甲型肝炎、腮腺炎、腎綜合征出血熱及腦膜炎球菌病,亦有針對13個疾病領域的23種在研疫苗。

另外,公司亦是國內唯一採用經獲批准新冠疫苗產品驗證的所有四種技術路線,即mRNA、滅活病毒、重組腺病毒載體及重組蛋白的COVID-19疫苗開發商。

於2018年、2019年及2020年,總收益分別為人民幣11.1億元人民幣(下同)、9.5億元及16.38億元。純利從2018年的1.01億元增至2019年的1.2億元,並進一步增至2020年的4億元,複合年增長率為98.7%,成為中國增長最快的國內疫苗市場參與者之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account